Small baby in a hospital

Trial cutting baby hospitalisations

A global trial has found that a new antibody treatment has the potential to significantly reduce baby hospitalisations.

An 80% reduction in hospitalisations can be achieved through protecting babies from a winter virus, with this coming thanks to the HARMONIE trial. The trial was conducted by the National Institute for Health and Care Research in collaboration with Sanofi and AstraZeneca, and involved 8,058 babies from the UK, France, and Germany. These babies were all under the age of 12 months and were approaching their first Respiratory Syncytial Virus (RSV) season.

As the leading cause of infant hospitalisation, RSV puts NHS resources under considerable pressure. More than 30,000 children under the age of five are hospitalised with RSV every year, with the virus also causing more than 20 and 30 infant deaths every year, this is due to some babies developing severe lung problems such as bronchiolitis and pneumonia.

NHE Static Quote trial

NIHR Director of Strategic Industry Relationships Dr Matthew Hallsworth said:

“HARMONIE is a fantastic example of industry and NIHR collaboration. NIHR was instrumental in delivering this study in both secondary and primary care across the country, with the first global participant recruited in a GP site in Nottingham. In addition, this study was the first commercial study that involved an NIHR Associate Principal Investigator, a scheme which encourages in-work training, building on practical experience for healthcare professionals starting their research career.”

The trial found that immediate protection against RSV can be given after a single dose of the nirsevimab antibody, with the potential to ease RSV infant hospitalisations by 83%, helping to ease pressures that the NHS faces over the winter period. Approval for the treatment has already been granted in the UK, with it also being considered for a national immunisation programme.

Experts at University Hospital Southampton, University of Southampton, St George’s University Hospital and the University of Nottingham co-led the HARMONIE study, with it being supported by the NIHR Southampton Clinical Research Facility and the NIHR Southampton Biomedical Research Centre. Half of the babies that were recruited for the trial were found by the NIHR through its Clinical Research Network

Professor Saul Faust, Director of NIHR Southampton CRF and co-leader of the study, also commented:

“These latest results show that this long-acting antibody is safe and could protect thousands of babies from hospitalisation when used in conditions similar to routine clinical practice. It is really important information for the UK to help decide on options for the future national RSV immunisation programme.”

 

Image credit: iStock

Website cover

NHE May/June 2024

Join the conversation shaping the future of healthcare.

Click below to read more!

More articles...

View all
Online Conference

Presenting

2024 Online Conferences

In partnership with our community of health sector leaders responsible for delivering the UK's health strategy across the NHS and the wider health sector, we’ve devised a collaborative calendar of conferences and events for industry leaders to listen, learn and collaborate through engaging and immersive conversation. 

All our conferences are CPD accredited, which means you can gain points to advance your career by attending our online conferences. Also, the contents are available on demand so you can re-watch at your convenience.

National Health Executive Podcast

Listen to industry leaders on everything within healthcare

Whether it's the latest advancements in medical technology, healthcare policies, patient care innovations, or the challenges facing healthcare providers, we cover it all.

 

Join us as we engage with top healthcare professionals, industry leaders, and policy experts to bring you insightful conversations that matter.